Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
The Food and Drug Administration approved Cobenfy on the strength of two encouraging company-sponsored five-week trials and other safety data. The latest results announced Thursday at the Psych ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will extend its leadership in the muscarinic drug class ...
7don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
The Associated Press on MSN19d
A promising schizophrenia drug showed mixed results. What does that mean for patients?The Food and Drug Administration approved Cobenfy on the strength of two encouraging company-sponsored five-week trials and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback